Clinical Management Guidelines for GATA2 Variants

This guide outlines clinical management guidelines for patients with a pathogenic or likely pathogenic variant in the GATA2 gene, particularly concerning myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It references the Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults, emphasizing that U.S. consensus practice guidelines are not yet developed. The document details the importance of clinical correlation with the patient's medical history and the role of genetic testing in informing management decisions. It presents various screening and surgical considerations, including baseline tests and individualized management strategies. The guide also discusses the implications of GATA2 deficiency, including increased cancer risks and other medical concerns, while stressing the importance of personalized risk management discussions between patients and healthcare providers. Additionally, it highlights the potential hereditary nature of GATA2 variants and the importance of family testing and awareness.